Molecular Devices Introduces FLIPR Tetra(TM) Screening System with Simultaneous 1536 Liquid Transfer
02 June 2004 - 7:30AM
PR Newswire (US)
Molecular Devices Introduces FLIPR Tetra(TM) Screening System with
Simultaneous 1536 Liquid Transfer SUNNYVALE, Calif., June 1
/PRNewswire-FirstCall/ -- Molecular Devices Corporation
(NASDAQ:MDCC) today announced the introduction of FLIPR Tetra(TM),
the first system that enables researchers to significantly increase
throughput of cell-based assays by measuring 1536 kinetic
measurements simultaneously. The FLIPR Tetra, which debuts today at
Molecular Devices' Drug Discovery Conference in Berkeley,
California, is the only microplate detection system that
simultaneously transfers liquid to 1536-well microplates,
significantly reducing screening time and reagent consumption. This
entirely new, modular system also offers traditional 96- and
384-well fluidics, easily convertible by the user within minutes,
providing a seamless transition between higher- volume assays to
those that require sub-microliter volume additions. FLIPR Tetra is
also the first FLIPR(R) system to offer an expanded set of
excitation wavelengths, significantly broadening its use beyond
traditional calcium mobilization and membrane potential assays.
"FLIPR is the most widely-used screening system for GPCR analysis,"
stated Michael L. Biros, Marketing Director for Drug Discovery
Instruments at Molecular Devices. "With FLIPR Tetra, researchers
can now increase the throughput and reduce the cost of their
calcium mobilization and membrane potential assays even
more-screening over 3,000 kinetic assays every six minutes using a
few thousand cells per assay." Commenting on the launch of the
FLIPR Tetra, Stephen J. Oldfield, Ph.D., Molecular Devices' Vice
President of Worldwide Marketing, stated, "Development of FLIPR
Tetra was guided by senior-level drug discovery managers striving
to reduce facilities and screening costs, as well as thousands of
FLIPR users looking to improve ease-of-use and robustness. Oldfield
further noted, "The FLIPR Tetra brings the multi-wavelength
capability that our FlexStation(TM) users have enjoyed to a
high-throughput platform, paving the way for multi- wavelength
applications. This new instrument platform also extends the user
base for our growing family of reagent kits, including Calcium 3
and membrane potential kits." Molecular Devices Corporation is a
leading supplier of high-performance bioanalytical measurement
systems that accelerate and improve drug discovery and other life
sciences research. The Company's systems and consumables enable
pharmaceutical and biotechnology companies to leverage advances in
genomics, proteomics and combinatorial chemistry by facilitating
the high-throughput and cost-effective identification and
evaluation of drug candidates. The Company's solutions are based on
its advanced core technologies that integrate its expertise in
engineering, molecular and cell biology and chemistry. Molecular
Devices enables its customers to improve research productivity and
effectiveness, which ultimately accelerates the complex process of
discovering and developing new drugs. This press release contains
"forward-looking" statements, including statements related to the
prospects for or potential customer use of the FLIPR Tetra system.
Any statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking
statements. Words such as "believes," "anticipates," "plans,"
"expects," "will," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors
that could cause the results of Molecular Devices Corporation to
differ materially from those indicated by these forward-looking
statements, including, among others, risks detailed from time to
time in the Company's SEC reports, including its Annual Report on
Form 10-K for the year ended December 31, 2003, as amended, and its
quarterly report on Form 10-Q for the quarter ended March 31, 2004.
Molecular Devices Corporation does not undertake any obligation to
update forward-looking statements. DATASOURCE: Molecular Devices
Corporation CONTACT: Tim Harkness of Molecular Devices Corporation,
+1-408-747-3533 Web site: http://www.moleculardevices.com/
Copyright
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Molecular Devices (MM) (NASDAQ): 0 recent articles
More Molecular Devices (MM) News Articles